[Federal Register Volume 81, Number 145 (Thursday, July 28, 2016)]
[Notices]
[Pages 49647-49648]
[FR Doc No: 2016-17860]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 4254-011]

Brentwood Dam Ventures, LLC; Notice of Proposed Termination of
Exemption by Implied Surrender and Soliciting Comments, Protests and
Motions To Intervene

    Take notice that the following hydroelectric proceeding has been
initiated by the Commission:

    a. Type of Proceeding: Proposed Termination of Exemption by Implied
Surrender.
    b. Project No.: 4254-011.
    c. Date Initiated: July 20, 2016.
    d. Exemptee: Brentwood Dam Ventures, LLC.
    e. Name and Location of Project: Exeter River Hydro #1 Project
located on the Exeter River, in Rockingham County, New Hampshire.
    f. Filed Pursuant to: 18 CFR 4.106.
    g. Exemptee Contact Information: Mr. Naoto Inoue, 25 Limerick Road,
Arundel, Maine 04046, Phone:<PHONE_NUMBER>.
    h. FERC Contact: Mr. Ashish Desai,<PHONE_NUMBER>,
<EMAIL_ADDRESS>    i. Deadline for filing comments, protests, and motions to intervene
is 30 days from the issuance date of this notice by the Commission. The
Commission strongly encourages electronic filing. Please file comments,
protests, and motions to intervene using the Commission's eFiling
system at http://www.ferc.gov/docs-filing/efiling.asp. Commenters can
submit brief comments up to 6,000 characters, without prior
registration, using the eComment system at http://www.ferc.gov/docs-filing/ecomment.asp. You must include your name and contact information
at the end of your comments. For assistance, please contact FERC Online
Support at<EMAIL_ADDRESS>(866) 208-3676 (toll free), or
(202) 502-8659 (TTY). In lieu of electronic filing, please send a paper
copy to: Secretary, Federal Energy Regulatory Commission, 888 First
Street NE., Washington, DC 20426. The first page of any filing should
include docket number P-4254-011.
    j. Description of Project Facilities: (1) An 110-foot-long, 15-
foot-high concrete dam; (2) a 24-acre reservoir; (3) an intake
structure; (4) turbine-generator units with an installed capacity of 72
kilowatts; and (5) appurtenant facilities.
    k. Description of Proceeding: The exemptee is in violation of
Standard Article 1 of the exemption, issued on December 1, 1981 (17
FERC ] 62,321), and the Commission's regulations at 18 CFR 4.106.
Article 1 provides, among other things, that the Commission reserves
the right to revoke an exemption if any term or condition of the
exemption is violated.
    The exemptee's failure to operate and maintain the project as
authorized by its exemption is a violation of Standard Article 1.
Commission records indicate that the project has not been operated
since 1998. The current exemptee acquired the project in February 2009
and has been unable to restore project operation. On December 19, 2013,
the exemptee filed a plan and schedule to restore project operation,
which Commission staff approved with the requirement that the exemptee
file quarterly progress reports starting October 1, 2014. The exemptee
did not file the first progress report. By letter on December 19, 2014,
Commission staff requested that the exemptee file the overdue progress
report. In response, on January 9, 2015, the exemptee filed a

request for an extension of time stating it was unable to move forward
with the approved plan and schedule and needed more time to reevaluate
and formulate a plan of action. By telephone on March 12, 2015,
Commission staff contacted the exemptee to inquire about the non-
operational status of the project. In response, the exemptee reiterated
its need for additional time and stated it was looking for a buyer for
the project. By letter on April 15, 2016, Commission staff again
requested that the exemptee file a plan and schedule to restore project
operation. In addition, Commission staff informed the exemptee that it
was non-compliant with the exemption and that failure to maintain and
operate the project as authorized would result in termination of the
exemption by the Commission. On April 27, 2016, the exemptee filed a
response stating the project was still for sale, but did not file a
plan and schedule or any other information regarding its efforts to
restore project operation.
    l. This notice is available for review and reproduction at the
Commission in the Public Reference Room, Room 2A, 888 First Street NE.,
Washington, DC 20426. The notice and other project records may also be
viewed on the Commission's Web site at http://www.ferc.gov/docs-filing/elibrary.asp. Enter the Docket number (P-4254-011) excluding the last
three digits in the docket number field to access the notice. You may
also register online at http://www.ferc.gov/docs-filing/esubscription.asp to be notified via email of new filings and issuances
related to this or other pending projects. For assistance, call toll-
free<PHONE_NUMBER> or email<EMAIL_ADDRESS>For TTY, call
(202) 502-8659.
    m. Individuals desiring to be included on the Commission's mailing
list should so indicate by writing to the Secretary of the Commission.
    n. Comments, Protests, or Motions to Intervene: Anyone may submit
comments, a protest, or a motion to intervene in accordance with the
requirements of Rules of Practice and Procedure, 18 CFR 385.210, .211,
and .214. In determining the appropriate action to take, the Commission
will consider all protests or other comments filed, but only those who
file a motion to intervene in accordance with the Commission's Rules
may become a party to the proceeding. Any comments, protests, or
motions to intervene must be received on or before the specified
comment date for the particular application.
    o. Filing and Service of Responsive Documents: Any filing must (1)
bear in all capital letters the title ``COMMENTS,'' ``PROTEST,'' or
``MOTION TO INTERVENE'' as applicable; (2) set forth in the heading the
name of the applicant and the project number of the application to
which the filing responds; (3) furnish the name, address, and telephone
number of the person protesting or intervening; and (4) otherwise
comply with the requirements of 18 CFR 385.2001 through 385.2005. All
comments, motions to intervene, or protests must set forth their
evidentiary basis and otherwise comply with the requirements of 18 CFR
4.34(b). All comments, protests, or motions to intervene should relate
to project works which are the subject of the implied surrender. A copy
of any protest or motion to intervene must be served upon each
representative of the applicant specified in the particular
application. If an intervener files comments or documents with the
Commission relating to the merits of an issue that may affect the
responsibilities of a particular resource agency, they must also serve
a copy of the document on that resource agency. A copy of all other
filings in reference to this application must be accompanied by proof
of service on all persons listed in the service list prepared by the
Commission in this proceeding in accordance with 18 CFR 4.34(b) and
385.2010.

    Dated: July 20, 2016.
Kimberly D. Bose,
Secretary.
[FR Doc. 2016-17860 Filed 7-27-16; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register Volume 82, Number 41 (Friday, March 3, 2017)]
[Notices]
[Pages 12457-12458]
[FR Doc No: 2017-04152]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0965]

Joint Meeting of the Nonprescription Drugs Advisory Committee and
the Drug Safety and Risk Management Advisory Committee; Notice of
Meeting; Establishment of a Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Nonprescription Drugs Advisory
Committee and the Drug Safety and Risk Management Advisory Committee.
The general function of the committees is to provide advice and
recommendations to the Agency on FDA's regulatory issues. The meeting
will be open to the public. FDA is establishing a docket for public
comment on this document.

DATES: The meeting will be held on April 4, 2017, from 8 a.m. to 5 p.m.

ADDRESSES: Tommy Douglas Conference Center, the Ballroom, 10000 New
Hampshire Ave., Silver Spring, MD 20903. The conference center's
telephone number is<PHONE_NUMBER>. Answers to commonly asked questions
including information regarding special accommodations due to a
disability, visitor parking, and transportation may be accessed at:
http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm. You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2017-N-0965 for ``Joint Meeting of the Nonprescription Drugs
Advisory Committee and the Drug Safety and Risk Management Advisory
Committee; Notice of Meeting; Establishment of a Public Docket; Request
for Comments.'' Received comments will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Moon Hee V. Choi, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX:<PHONE_NUMBER>, email<EMAIL_ADDRESS>or FDA Advisory
Committee Information Line, 1-800-741-8138<PHONE_NUMBER> in the
Washington, DC area). A notice in the Federal Register about last
minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the Agency's Web site
at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to
the

appropriate advisory committee meeting link, or call the advisory
committee information line to learn about possible modifications before
coming to the meeting.

SUPPLEMENTARY INFORMATION:
    Agenda: The committees will discuss safety issues associated with
over-the-counter analgesic combination products used for upset stomach
(i.e., heartburn, nausea, fullness, belching, gas, acid indigestion,
and/or sour stomach) and hangover indications under the Internal
Analgesic and Antacid monographs in 21 CFR part 343 and 21 CFR part
331, respectively. The committees will also be asked to discuss the
hangover indication under the Overindulgence, Internal Analgesic, and
Stimulant monographs in 21 CFR part 357 subpart J, 21 CFR part 343, and
21 CFR part 340, respectively.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committees.
All electronic and written submissions submitted to the Docket (see the
Addresses section) on or before March 21, 2017, will be provided to the
committees. Oral presentations from the public will be scheduled
between approximately 1 p.m. and 2 p.m. Those individuals interested in
making formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before March 13, 2017. Time allotted for
each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by March 14, 2017.
    Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
    FDA is establishing a docket for public comment on this meeting.
The docket number is FDA-2017-N-0965. The docket will close on April 3,
2017. Comments received on or before March 21, 2017, will be provided
to the committees. Comments received after that date will be taken into
consideration by the Agency.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Moon Hee V. Choi at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: February 28, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2017-04152 Filed 3-2-17; 8:45 am]
 BILLING CODE 4164-01-P